Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumbricus rubellus extract - Dexa Medica

Drug Profile

Lumbricus rubellus extract - Dexa Medica

Alternative Names: Disolf; DLBS-1033; Lumbricus low molecular weight proteins; Red earthworm extract

Latest Information Update: 18 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dexa Medica
  • Class Alternative medicine; Enzymes; Thrombolytics; Traditional Chinese medicine
  • Mechanism of Action Fibrin inhibitors; Fibrinogen inhibitors; Fibrinolysis stimulants; Fibrinolytic agents; Janus kinase 1 inhibitors; Matrix metalloproteinase 9 inhibitors; NF-kappa B inhibitors; Platelet aggregation inhibitors; STAT1 transcription factor inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stroke
  • Phase II/III Acute coronary syndromes; Peripheral arterial disorders

Most Recent Events

  • 01 Apr 2020 Dexa Laboratories Of Biomolecular Science initiates enrolment in a phase II/III trial in Stroke (Adjunctive treatment) in Indonesia (PO) (NCT04425590)
  • 01 Jul 2018 Dexa Medica terminates a phase II/III trial due to the recruitment rate was too low for Peripheral arterial disorders in Indonesia (NCT02145988)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top